Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose randomized crossover bioequivalence study of generic apixaban vs Eliquis in healthy Thai volunteers under fasting conditions
TCTR20210824006Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (2 arms), sponsored by International Bio Service. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on TCTR20210824006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210824006.